Wendy Mcdermott
Human Resources Officer bij LEXICON PHARMACEUTICALS, INC.
Vermogen: 89 580 $ op 31-05-2024
Actieve functies van Wendy Mcdermott
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. | Human Resources Officer | 01-01-2022 | - |
Loopbaan van Wendy Mcdermott
Eerdere bekende functies van Wendy Mcdermott
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| Sanofi Corp. | Human Resources Officer | 01-01-2017 | 01-01-2019 |
Cornerstone Pharmaceuticals, Inc.
 Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Human Resources Officer | 01-01-2019 | - |
Opleiding van Wendy Mcdermott
| State University of New York College at Plattsburgh | Undergraduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 5 |
Operationeel
| Human Resources Officer | 3 |
| Undergraduate Degree | 1 |
Sectoraal
| Health Technology | 2 |
| Consumer Services | 2 |
| Commercial Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| LEXICON PHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Commercial Services |
| Sanofi Corp. |
- Beurs
- Insiders
- Wendy Mcdermott
- Ervaring
